Ellen Damgaard Andersen

A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation

2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation

Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation

Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary

Pharmacology and Management of the Vitamin K Antagonists

Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach

Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation

Sorting Signals That Mediate Traffic of Chitin Synthase III between the TGN/Endosomes and to the Plasma Membrane in Yeast

Oral Anticoagulant Therapy

Intracranial and fatal bleeding according to indication for long‐term oral anticoagulant therapy

Newly Detected Atrial Fibrillation and Compliance With Antithrombotic Guidelines

Validation of Clinical Classification Schemes for Predicting Stroke

Emergency Hospitalizations for Adverse Drug Events in Older Americans

The Science of Stroke: Mechanisms in Search of Treatments

Impaired PIEZO1 function in patients with a novel autosomal recessive congenital lymphatic dysplasia

The primary periodic paralyses: diagnosis, pathogenesis and treatment

ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

A test of financial incentives to improve warfarin adherence

Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

Antithrombotic Therapy for VTE Disease

Platelet Activation and Atherothrombosis

GRADE guidelines: 3. Rating the quality of evidence

Stroke

Atrial fibrillation and atrial enlargement in patients with mitral stenosis

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Antithrombotic and Thrombolytic Therapy for Ischemic Stroke

Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations

Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation

Antithrombotic Therapy in Atrial Fibrillation

A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial Fibrillation

Risks and Benefits of Combined Maze Procedure for Atrial Fibrillation Associated With Organic Heart Disease11It was presented at the 43rd Annual Scientific Session, American College of Cardiology, Atlanta, Georgia, March 1994.

Effect of Study Setting on Anticoagulation Control

Combined Aspirin–Oral Anticoagulant Therapy Compared With Oral Anticoagulant Therapy Alone Among Patients at Risk for Cardiovascular Disease

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial

Defective Potassium Channel Kir2.1 Trafficking Underlies Andersen-Tawil Syndrome

Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: An exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials

Stroke risk in an elderly population with atrial fibrillation

Oral Anticoagulants vs Aspirin in Nonvalvular Atrial Fibrillation

Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation

The Pharmacology and Management of the Vitamin K Antagonists

Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment

Mitral valve surgery and atrial fibrillation: is atrial fibrillation surgery also needed?

Atrial fibrillation and stroke prevention

Antithrombotic Therapy in Atrial Fibrillation

Golgi Export of the Kir2.1 Channel Is Driven by a Trafficking Signal Located within Its Tertiary Structure

Hemorrhagic Complications of Anticoagulant Treatment

Antithrombotic Therapy for Atrial Fibrillation

The familial periodic paralyses and nondystrophic myotonias

Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization

Amyotrophic Lateral Sclerosis

Hemorrhagic Complications of Anticoagulant Treatment

Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited

Antithrombotic Therapy in Atrial Fibrillation

Guidelines for the Early Management of Patients With Acute Ischemic Stroke

Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

Oral Anticoagulant Therapy in Patients with Nonrheumatic Atrial Fibrillation and Risk of Bleeding

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

Molecular Basis of Genetic Heterogeneity: Role of the Clinical Neurologist

Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation

Selecting Patients With Atrial Fibrillation for Anticoagulation

American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons

A Novel Form of Short QT Syndrome (SQT3) Is Caused by a Mutation in the KCNJ2 Gene

Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension

ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease

Effects of Fixed Low-Dose Warfarin, Aspirin-Warfarin Combination Therapy, and Dose-Adjusted Warfarin on Thrombogenesis in Chronic Atrial Fibrillation

American Heart Association/American College of Cardiology Foundation guide to warfarin therapy11The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.This statement has been co-published in the April 1, 2003, issue of Circulation.This statement was approved by the American Heart Association Science Advisory and Coordinating Committee in October 2002 and by the American College of Cardiology Board of Trustees in February 2003. A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0254. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 410-528-4426, fax 410-528-4264, or e-mail klbradle@lww.com. To make photocopies for personal or educational use, call the Copyright Clearance Center, 978-750-8400.

Factors Associated With Ischemic Stroke During Aspirin Therapy in Atrial Fibrillation

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks

Neural Science

Avoiding Central Nervous System Bleeding During Antithrombotic Therapy

Worldwide Epidemiology of Atrial Fibrillation

2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Behavioral Economics and the Retirement Savings Crisis

Atrial Fibrillation and Thromboembolism: A Decade of Progress in Stroke Prevention

Molecular Basis of Arrhythmias

The Emergence of Modern Neuroscience: Some Implications for Neurology and Psychiatry

Hypermorphic mutation of the voltage-gated sodium channel encoding gene Scn10a causes a dramatic stimulus-dependent neurobehavioral phenotype

Fixed Minidose Warfarin and Aspirin Alone and in Combination vs Adjusted-Dose Warfarin for Stroke Prevention in Atrial Fibrillation

Atrial fibrillation in the Wolff-Parkinson-White syndrome

DC-Conversion of Atrial Fibrillation after Mitral Valve Operation.An Analysis of the Long-term Results

INTERMITTENT MUSCULAR WEAKNESS, EXTRASYSTOLES, AND MULTIPLE DEVELOPMENTAL ANOMALIES